Get the Stockscreener App
0.8947
9.47%
-0.0936
After Hours:
.89
-0.0047
-0.53%
Barinthus Biotherapeutics Plc Adr stock is traded at $0.8947, with a volume of 142.28K.
It is down -9.47% in the last 24 hours and down -39.14% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
See More
Previous Close:
$0.9883
Open:
$1.02
24h Volume:
142.28K
Relative Volume:
3.43
Market Cap:
$35.99M
Revenue:
$13.42M
Net Income/Loss:
$-73.35M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-56.34M
1W Performance:
-7.78%
1M Performance:
-39.14%
6M Performance:
-61.10%
1Y Performance:
-69.67%
1-Day Range:
$0.8947
$1.02
1-Week Range:
$0.81
$1.02
52-Week Range:
$0.81
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
UNIT 6-10, ZEUS BUILDING, DIDCOT
Compare BRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BRNS | 0.8947 | 35.99M | 13.42M | -73.35M | -56.34M | 0.00 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewswire Inc.
Market Update: Barinthus Biotherapeutics Plc. ADR (BRNS) Sees Negative Movement, Closing at 2.00 – DWinneX - The Dwinnex
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 - Investing.com India
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
ANVS Stock Quote Price and Forecast - CNN
TPST Stock Quote Price and Forecast - CNN
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):